# Seaport Therapeutics, Inc.: financial statements, quarterly

SPTX · Nasdaq · CIK 2042347 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sptx.md) · [Financials](/companies/sptx/financials.md) · [Filings](/companies/sptx/filings.md) · [Insiders](/companies/sptx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sptx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [10.5](/filings/0001193125-26-260678.md) | [13.4](/filings/0001193125-26-329537.md) | [21.4](/filings/0001193125-26-260678.md) | [24.6](/filings/0001193125-26-329537.md) |
| Operating income | $m | [(16.2)](/filings/0001193125-26-260678.md) | [(18.5)](/filings/0001193125-26-329537.md) | [(27.5)](/filings/0001193125-26-260678.md) | [(65.8)](/filings/0001193125-26-329537.md) |
| Income tax | $m | [0.0](/filings/0001193125-26-260678.md) | [0.1](/filings/0001193125-26-329537.md) | [0.5](/filings/0001193125-26-260678.md) | [0.3](/filings/0001193125-26-329537.md) |
| Net income | $m | [(13.1)](/filings/0001193125-26-329537.md) | [(15.1)](/filings/0001193125-26-329537.md) | [(25.4)](/filings/0001193125-26-329537.md) | [(62.6)](/filings/0001193125-26-329537.md) |
| Diluted EPS | $ per share | [(5.65)](/filings/0001193125-26-260678.md) | [(6.40)](/filings/0001193125-26-329537.md) | [(10.34)](/filings/0001193125-26-260678.md) | [(1.78)](/filings/0001193125-26-329537.md) |
| Basic EPS | $ per share | [(5.65)](/filings/0001193125-26-260678.md) | [(6.40)](/filings/0001193125-26-329537.md) | [(10.34)](/filings/0001193125-26-260678.md) | [(1.78)](/filings/0001193125-26-329537.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [46.0](/filings/0001193125-26-329537.md) | [52.9](/filings/0001193125-26-260678.md) | [64.2](/filings/0001193125-26-329537.md) |
| Current assets | $m | not reported | not reported | not reported | [223](/filings/0001193125-26-329537.md) | [188](/filings/0001193125-26-260678.md) | [282](/filings/0001193125-26-329537.md) |
| Total assets | $m | not reported | not reported | not reported | [249](/filings/0001193125-26-329537.md) | [228](/filings/0001193125-26-260678.md) | [442](/filings/0001193125-26-329537.md) |
| Current liabilities | $m | not reported | not reported | not reported | [12.8](/filings/0001193125-26-329537.md) | [14.2](/filings/0001193125-26-260678.md) | [15.7](/filings/0001193125-26-329537.md) |
| Total liabilities | $m | not reported | not reported | not reported | [16.2](/filings/0001193125-26-329537.md) | [18.0](/filings/0001193125-26-260678.md) | [19.1](/filings/0001193125-26-329537.md) |
| Shareholders' equity | $m | [(24.8)](/filings/0001193125-26-329537.md) | [(36.2)](/filings/0001193125-26-329537.md) | [(49.5)](/filings/0001193125-26-329537.md) | [(92.5)](/filings/0001193125-26-329537.md) | [(116)](/filings/0001193125-26-329537.md) | [423](/filings/0001193125-26-329537.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.2)](/filings/0001193125-26-260678.md) | [(15.3) d](/filings/0001193125-26-329537.md) | [(20.2)](/filings/0001193125-26-260678.md) | [(26.1) d](/filings/0001193125-26-329537.md) |
| Capital expenditure | $m | [0.1](/filings/0001193125-26-260678.md) | [0.3 d](/filings/0001193125-26-329537.md) | [0.0](/filings/0001193125-26-260678.md) | [0.0 d](/filings/0001193125-26-329537.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.3](/filings/0001193125-26-260678.md) | [2.4](/filings/0001193125-26-329537.md) | [2.5](/filings/0001193125-26-260678.md) | [35.2](/filings/0001193125-26-329537.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 53,530,550 at 2026-07-27, from the cover of the [10-Q filed 2026-08-03](/filings/0001193125-26-329537.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.